Evidence map›Paper›PMID 29633600›Full record

ArticleCell journal2018

The Role of MicroRNA Signature as Diagnostic Biomarkers in Different Clinical Stages of Colorectal Cancer.

Sara Eslamizadeh, Mansour Heidari, Shahram Agah, Ebrahim Faghihloo, Hossein Ghazi, Alireza Mirzaei, Abolfazl Akbari

Abstract read
In one paragraph

Article in Cell journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Exploring the interplay betweenFrontiers in microbiology · 2023
    Article
  8. Biomedicines · 2022
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Function and mechanisms of microRNA-20a in colorectal cancer.Experimental and therapeutic medicine · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sara EslamizadehDepartment of Molecular Genetics, Marvdasht Branch, Islamic Azad University, Marvdasht, Iran.
Mansour HeidariDepartment of Molecular Biology and Genetics, Bushehr Branch, Islamic Azad University, Bushehr, Iran.
Shahram AgahColorectal Research Center, Iran University of Medical Sciences, Tehran, Iran.
Ebrahim FaghihlooDepartment of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hossein GhaziOphthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Alireza MirzaeiBone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran.
Abolfazl AkbariColorectal Research Center, Iran University of Medical Sciences, Tehran, Iran.Electronic address:akbariia2006@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesColorectal cancer (CRC) is one of the most common cancers and a major cause of cancer-related death worldwide. The early diagnosis of colorectal tumors is one of the most important challenges in cancer management. MicroRNAs (miRNAs) have provided new insight into CRC development and have been suggested as reliable and stable biomarkers for diagnosis and prognosis. This study's objective was to analyze the differential expression of miRNAs at differentstages of CRC searching for possible correlation with clinicopathological features to examine their potential value as diagnostic biomarkers. MATERIALS AND

methodsIn this case-control study, plasma and matched tissue samples were collected from 74 CRC patients at stage II-IV as well as blood samples from 32 healthy controls. After exhaustive study of the current literature, eight miRNAs including miR-200c, 20a, 21, 31,135b, 133b,145 and let-7g were selected. The expression level of the miRNAs was assayed by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). Statistical analysis, including t test , Mann-Whitney U, Kruskall-Wallis tests and receiver operating characteristic (ROC) curve was applied, where needed.

resultsSignificantly elevated levels of miR-21, miR-31, miR-20a, miR-135b, and decreased levels of miR- 200c, miR-145 and let-7 g were detected in both plasma and matched tissue samples compared to the healthy group (P<0.05). However, no significant differences were observed in the expression level of plasma and tissue miR-133b (P>0.05). ROC for tissue miRNAs showed an area under the ROC curve (AUC) of 0.98 and P<0.001 for miR-21, 0.91 and P<0.001 for miR-135b, 0.91 and P<0.001 for miR-31, and 0.92 and P<0.001 for miR-20a.

conclusionsOur results indicate that the expression levels of microRNAs are systematically altered in CRC tissue and plasma. In conclusion, detection of miR-21, miR-135b, miR-31 and miR-20a levels in the tissue might be helpful to illuminate the molecular mechanisms underlying CRC carcinogenesis and serve as tumor-associated biomarkers for diagnosis.

Indexed as

BiomarkerBloodColorectal CancerDiagnosisMicroalgaeMicroRNA

Identifiers

PMID29633600
PMCPMC5893294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.